Artialis: Passion for Healthy Aging
Artialis, a leading Contract Research Development Organization (CRDO), specializes in musculoskeletal health. Offering a comprehensive range of services from preclinical research to post-marketing surveillance.
Founded in 2010, Artialis emerged from the University of Liege’s Bone and Cartilage Research Unit. With a strong foundation in scientific research, Artialis has grown into a trusted partner for pharmaceutical and biotech companies worldwide.
Over the past 14 years, Artialis has successfully completed 142 R&D projects, leveraging the combined expertise of its team, which boasts over 75 years of experience in the industry. This wealth of knowledge allows Artialis to provide tailored solutions and navigate the complexities of product development.
Driven by a commitment to client satisfaction, the company has achieved a remarkable 90% satisfaction rate.
Lear more: www.artialis.com
A LEADING POSITION AND
AN INTERNATIONAL DEPLOYMENT
64 +
countries
involved
20 000 +
investigational
Centres
3 million +
patients
in database
50 000 +
users
worlwide
LATEST NEWSOUR NEWS >
June 26, 2025
June 30 – 4:00 PM to 5:15 PM (CET) xShare, an EU-funded project, strengthens procurement capabilities in digital health by translating the European Electronic Health Record Exchange Format (EEHRxF) into concrete requirements for tenders. This inaugural webinar presents key EU rules and promotes the procurement of interoperable solutions. It aims to raise awareness, share innovative […]
June 26, 2025
June 25–27 – JETRO – Japan External Trade Organization Pavilion – Osaka Booth Hall 6‑A, A‑0408 Philippe Haran – MD, is representing Telemedicine Technologies at the Japan Health Exhibition 2025, as a guest of Micron, Inc., a valued member of our CROAlliance partner. At Micron’s booth, he’s engaging with healthcare leaders and exploring collaboration opportunities […]
June 26, 2025
Applied Clinical Trials Online At a time when artificial intelligence (AI) is redefining industries at an unprecedented pace, the pharmaceutical sector stands on the brink of a progressive transformation. AI is not just a tool but a catalyst that promises to accelerate drug development timelines in ways we’ve never seen before. However, the true potential […]